Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Alto Neuroscience has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Alto Neuroscience's investors include Franklin Templeton, Eli Lilly, Valor Equity Partners, Vivo Capital, Commodore Capital.
Alto Neuroscience is headquartered in Los Altos, United States.
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Alto Neuroscience is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alto Neuroscience — Funding & Investors." VCBacked, July 13, 2026, https://www.vcbacked.co/company/alto-neuroscience. Accessed September 13, 2026.
VCBacked. (2026). Alto Neuroscience — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/alto-neuroscience
{{cite web |title=Alto Neuroscience — Funding & Investors |url=https://www.vcbacked.co/company/alto-neuroscience |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated